This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Rozlytrek (entrectinib)
General Description:
Rozlytrek (entrectinib) is an oral targeted therapy used for the treatment of NTRK-positive solid tumors and ROS1-positive metastatic non-small cell lung cancer (NSCLC). It works by inhibiting specific proteins that drive cancer growth, helping to slow tumor progression and improve patient outcomes.
Rozlytrek is administered orally as capsules, with dosage and treatment schedules tailored by a healthcare professional based on individual patient needs and tolerance.
Getting Rozlytrek (entrectinib) in India
Rozlytrek is approved by multiple international regulatory agencies, including the FDA (U.S.), EMA (Europe), Health Canada, and PMDA (Japan). While not yet widely available in India, patients can access it legally through a Named Patient Program (NPP) under the guidance of a licensed physician.
MitoGENE helps Indian patients obtain Rozlytrek safely, handling all regulatory approvals, import permits, and logistics for a secure and compliant process.
Disease Indication:
• Solid Tumors / NTRK-positive tumors and ROS1-positive NSCLC
Manufacturer:
Genentech, Inc
Usage:
Oral Capsules
Medicine Approved By:
• Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Health Canada
• Pharmaceuticals and Medical Devices Agency (PMDA)
Available Dosage Form & Package:
• 100 mg capsules, 30 capsules per pack
• 200 mg capsules, 90 capsules per pack
Shipping:
Room Temperature Shipping
Rozlytrek is shipped at a controlled room temperature (15–25°C) to ensure stability and effectiveness. Standard shipping procedures are followed to maintain the medication’s quality throughout transit.
How to Access Rozlytrek (entrectinib) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Rozlytrek (entrectinib) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:
